88 results on '"Green, Damian"'
Search Results
2. Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma
3. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy
4. Optimizing Autologous Stem Cell Transplantation in Multiple Myeloma: The Impact of Intensive Chemomobilization
5. Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma
6. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
7. Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling
8. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
9. Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients
10. The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model
11. Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma
12. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy
13. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies
14. Answering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
15. Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis
16. Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myeloma
17. Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma
18. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission
19. Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment
20. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model
21. Long-Term Outcomes of Patients with Persistent Indolent B Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation
22. Humoral and cellular responses to SARS-CoV-2 vaccines before and after chimeric antigen receptor–modified T-cell therapy
23. Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy
24. Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
25. Plasma Cell Leukemia: A Multicenter Retrospective Study of 130 Patients
26. Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)
27. Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
28. Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model
29. Post-CAR-T Checkpoint Inhibition Can Result in Durable Responses in a Minority of Patients with Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL): Results of a Phase 2 Study of Nivolumab after CAR-T Failure
30. Identification and Prediction of Severe Hematologic Toxicity after CAR T-Cell Therapy Using Machine Learning-Based Time-Series Clustering
31. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model
32. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease
33. Revisiting the Utility of Granulocyte Colony-Stimulating Factor Post-Autologous Hematopoietic Stem Cell Transplantation for Outpatient-Based Transplantations
34. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates
35. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
36. P-001 The bone marrow stroma influences extrinsic apoptotic signaling and results in resistance to BCMA CAR-T cell induced cell death
37. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy
38. Alternating the Administration of Ixazomib and Lenalidomide As Maintenance Therapy after Autologous Transplant for Multiple Myeloma
39. Regulatory T Cell Depletion during Stem Cell Mobilization Enhances Anti-Myeloma Immunity after Experimental Autologous Stem Cell Transplantation
40. Long-term Follow-up of CD20-directed Chimeric Antigen Receptor Adoptive T-cell Therapy
41. 228 - Safety and Efficacy Comparison of Two Anakinra Dose Regimens for Refractory CRS or Neurotoxicity after CAR T-Cell Therapy
42. 225 - High Efficacy and Low Toxicity of MB-106, a Third Generation CD20 Targeted CAR-T for Treatment of Relapsed/Refractory B-NHL and CLL
43. KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
44. Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL
45. Development of Astatine-211 (211At)-Based Anti-CD123 Radioimmunotherapy for Acute Leukemias and Other CD123+ Hematologic Malignancies
46. 484 - Phase II Study of Mega-Dose 90Y-Ibritumomab Tiuxetan, Fludarabine and Low-Dose TBI Followed By Allogeneic Hematopoietic Transplantation for Relapsed or Refractory Aggressive Large B-Cell Lymphoma: Long-Term Outcomes
47. 418 - Infectious Complications and Humoral Immunity after BCMA-Directed Chimeric Antigen Receptor T-Cell Therapy in Adults with Multiple Myeloma
48. 57 - A Phase I Trial of First-in-Human Alpha-Emitter Astatine-211-Labeled Anti-CD45 Antibody (211At-BC8-B10) in Combination with Fludarabine and TBI As Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS): Preliminary Results of Dose Escalation
49. Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
50. Investigation of Monocarbon Carboranes as Pendant Groups for Labeling Small Molecules with Astatine-211
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.